Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25174124 | 0.95 | CYP3A4 (0.50) | CYP3A4TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL19348586 | 0.86 | CYP3A4 (0.43) | CYP3A4TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL25170072 | 0.86 | CYP3A4 (0.43) | CYP3A4TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL104844 | 0.83 | CYP3A4 (0.68) | CYP3A4TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL31023525 | 0.80 | CYP3A4 (0.65) | CYP3A4TSHRMEN1KMT2AALDH1A1 | |
| Methane SCHEMBL28409090 | 0.80 | CYP3A4 (0.65) | CYP3A4TSHRMEN1KMT2AALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL11326091 | 0.80 | CYP3A4 (0.65) | CYP3A4TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL11585764 | 0.80 | CYP3A4 (0.73) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL25176409 | 0.78 | CYP3A4 (0.62) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL2156671 | 0.78 | CYP3A4 (0.55) | CYP3A4TSHRMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3222624-B1 | IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME | CENTRAL GLASS CO LTD (JP) | 2019-11-06 | — | — | EP | disclosed |
| US-10287165-B2 | Imidic acid compound having divalent anion and process for producing the same | CENTRAL GLASS CO., LTD. (JP) | 2019-05-14 | — | — | US | disclosed |
| EP-3222624-A1 | IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME | Central Glass Co., Ltd. (JP) | 2017-09-27 | — | — | EP | disclosed |
| US-20170267528-A1 | IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME | CENTRAL GLASS CO., LTD. (JP) | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267528-A1 | IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME | CA2, CA6, CHRM1 | CYP3A4 415/4885TSHR 929/4885MEN1 233/4885 |
| US-10287165-B2 | Imidic acid compound having divalent anion and process for producing the same | CA2, CA6, CHRM1 | CYP3A4 415/4885TSHR 929/4885MEN1 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.